ニュース · QuantAbundancia

Zacks1d agoneutral

Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?

NTLA advances late-stage studies for nex-z and starts FDA filing for lonvo-z, positioning its pipeline for potential long-term growth.

Zacks1d agoneutral

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.

MarketBeat4d agoneutral

CRISPR Therapeutics Enters 'Second Phase' as CASGEVY Momentum Builds, Pipeline Data Looms

CRISPR Therapeutics (NASDAQ:CRSP) Chief Executive Officer Sam Kulkarni said the company is entering a “second phase” as it moves beyond the initial launch of CASGEVY and prepares for data from multiple pipeline programs over the next 12 to 18 months. Speaking at a Bank of America fireside chat host

CRSP VRTX

Zacks12d agoneutral

VRTX's Alyftrek, Journavx & Casgevy See Strong Momentum in Q1 Earnings

Vertex's new drugs are gaining momentum as Alyftrek tops $1 billion in sales and Journavx prescriptions accelerate.

CRSP VRTX

Zacks12d agoneutral

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

CRSP

Zacks15d agoneutral

CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Lags Revenue Estimates

CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of -12.39% and -82.62%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

CRSP

Motley Fool20d agoneutral

What's the Next Big Thing After GLP-1 Drugs? CRISPR Therapeutics May Have the Answer.

The biotech's candidate may treat a great number of illnesses that have one thing in common.

CRSP

Simply Wall St.21d agoneutral

Why CRISPR Therapeutics (CRSP) Is Down 10.1% After Casgevy’s Strong Early Launch Metrics And Earnings Hopes

In late April 2026, analysts highlighted expectations for higher year-over-year earnings and revenue at CRISPR Therapeutics ahead of its March-quarter report, alongside strong launch metrics for Casgevy, the gene therapy it co-commercializes with Vertex Pharmaceuticals. An interesting angle for investors is how Casgevy’s early commercial uptake and growing treated-patient base may influence perceptions of CRISPR Therapeutics’ broader gene-editing platform and revenue potential. With the...

CRSP VRTX

Zacks21d agoneutral

CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know

CRISPR Therapeutics AG (CRSP) reached $50.71 at the closing of the latest trading day, reflecting a -2.59% change compared to its last close.

CRSP

Motley Fool21d agoneutral

3 Growth Stocks That Could Generate 10X Returns

These stocks come with risk, but they also have some exciting long-term growth opportunities.

CRSP

Zacks22d agoneutral

Why the Market Dipped But CRISPR Therapeutics AG (CRSP) Gained Today

The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $52.06, representing a +2.1% change from its previous close.

CRSP